Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust ... Read More